Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and related technologies for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia and Poland. The company's principal products include CelGro, a naturally derived collagen medical device for soft tissue repair that is under clinical trials for use as an augment to the surgical repair of tendons, peripheral nerves, bones, and articular cartilage; and Ortho-ATI, an autologous tenocyte implantation for chronic treatment resistant tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation for the treatment of symptomatic defects of the articulating cartilage of the joints, primarily in the knee and ankle. Orthocell Limited was founded in 2006 and is based in Murdoch, Australia.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 8 9360 2888
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$945,657.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Orthocell (ASX:OCC) Frequently Asked Questions
What is Orthocell's stock symbol?
Orthocell trades on the ASX under the ticker symbol "OCC."
Has Orthocell been receiving favorable news coverage?
News stories about OCC stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Orthocell earned a coverage optimism score of 1.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Orthocell.
Who are some of Orthocell's key competitors?
Some companies that are related to Orthocell include Exicure (XCUR), Ergomed (ERGO), Exicure (XCUR), Antibe Therapeutics (ATE), Fennec Pharmaceuticals (FRX), Helix Biopharma (HBP), Enochian Biosciences (ENOB), CorMedix (CRMD), Senesco Technologies (ELOX), Ampliphi Biosciences (APHB), CorMedix (CRMD), Faron Pharmaceuticals Oy (FARN), Medicenna Therapeutics (MDNA), Burcon NutraScience (BU) and OncoCyte (OCX).
What other stocks do shareholders of Orthocell own?
Who are Orthocell's key executives?
Orthocell's management team includes the folowing people:
- Dr. Stewart James Washer B.Sc., BSc (Hons), Ph.D., Exec. Chairman (Age 49)
- Mr. Paul Anderson, CEO, MD & Exec. Director (Age 53)
- Ms. Nicole Telford, Chief Financial Officer
- Prof. Ming Hao Zheng, Chief Scientific Officer and Member of Medical & Scientific Advisory Board
- Monique Cannon, Regulatory Affairs & Compliance Mang.
What is Orthocell's stock price today?
One share of OCC stock can currently be purchased for approximately A$0.30.
How big of a company is Orthocell?
What is Orthocell's official website?
How can I contact Orthocell?
The company can be reached via phone at 61 8 9360 2888.
MarketBeat Community Rating for Orthocell (ASX OCC)
MarketBeat's community ratings are surveys of what our community members think about Orthocell and other stocks. Vote "Outperform" if you believe OCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCC will underperform the S&P 500 over the long term. You may vote once every thirty days.
